QT Imaging (QTI) Q2 2026 Earnings Call Transcript
QT Imaging Holdings (QTI) reported Q2 2026 revenue of $7.4 million, up 103% year over year, driven by 15 scanner shipments. First-half revenue was $14 million. Fiscal 2026 guidance calls for about $39 million revenue. Q2 gross margin was 41%; operating loss $1.9 million and net loss $11.1 million. Company extended debt to 2029 and raised $10 million via an offering.
How this was made
The 30-second read
Why it matters
Traders can update models using the disclosed FY2026 revenue target (~$39M), the H2 scanner shipment plan (15 in Q3, 17 in Q4), and the amended term loan terms (rate up to 12%, maturity extended to Mar. 31, 2029).
Market read
This is a primary earnings-call disclosure with forward guidance, shipment cadence, and financing terms that can drive near-term repricing.
What to watch
Gross margin is pressured by higher weighted average inventory cost for U.S. sales (41% vs 50% prior year), and operating expenses are rising due to sales and shifting clinical study spend into H2.
Background
QT Imaging held its Q2 2026 earnings call, covering financial results, guidance, manufacturing expansion, regulatory progress, and financing updates.
Ticker impact
QT Imaging reported Q2 revenue of $7.4M (+103% YoY), guided FY2026 revenue to about $39M, and detailed shipment ramp plans.
Bias to the upside if investors focus on the reaffirmed FY2026 revenue target and shipment ramp, but dilution/financing and rising operating loss could cap upside.
Guidance ($39M) and H2 shipment plan (15 in Q3, 17 in Q4) are concrete forward indicators, while the amended term loan raises the interest rate to 12% and highlights ongoing losses (net loss $11.1M).
Market effects
Breast imaging reimbursement and regulatory execution (Category III CPT effective Jan. 1, 2027, zero-483 FDA inspection) can improve sentiment for quantitative imaging device developers.
Israel and Saudi clearances plus a planned scanner placement at Rambam suggest incremental international commercialization momentum.
International regulatory footprint expansion and reimbursement pathway progress may support broader adoption narratives for medical imaging platforms.
Counterpoint
Despite the revenue surge, the company is still reporting large net losses and higher interest costs, so the guidance may be sensitive to shipment execution and payer adoption timing.
Key entities
- companyQT Imaging Holdings, Inc.
Subject of the earnings call; reported Q2 results, reaffirmed FY2026 revenue guidance, and discussed regulatory, manufacturing, and financing updates.
- lenderLynrock Lake
Amended QT Imaging’s senior secured term loan, extending maturity to March 31, 2029 and increasing the interest rate to 12%.
- regulatorAmerican Medical Association
Approved a dedicated Category III CPT reimbursement code for QT Imaging’s modality, effective Jan. 1, 2027.
- regulatorFDA
Completed QT Imaging’s first routine FDA inspection with zero Form 483 observations.
- clinical partnerMayo Clinic
Reported feasibility study agreement between QT Imaging scans and MRI for identifying suspicious lesions.
